Istar Medical Corporate Presentation

Home , Alcon

Corporate Presentation OCTOBER 2020

Next Generation Devices to Treat Glaucoma iSTAR Medical

Investors Company Highlights ISO 13485 • Private VC-backed company

• Targeting the MIGS* segment: fastest growing segment in Ophthalmic devices

• Lead product MINIject™ expected to provide best-in- class performance

• Primary Endpoints met in First-In-Human and CE clinical trials

• Regulatory Plans setup to achieve CE mark in 2021, and FDA clearance in 2024

• Completed €40M Series-C financing in July 2019

(*) Micro-invasive Glaucoma surgery

Board of Directors Management Team Scientific & Clinical Advisors

Michel Lussier Michel Vanbrabant Chairman of the Board CEO Ike Ahmed, MD Christoph Hirneiss, • CEO of Metronom Health, Chairman of Celyad • Formerly with Abbott, St.Jude Medical, PneumRx (Boston Toronto, Canada MD, Ph.D. Scientific) Munich, Germany

Lionel Carnot Katya Smirnyagina Zubair Hussain Stefan Uhrlandt • Partner, Earlybird Philippe Denis, Julian Garcia Feijoo, • Partner, Capricorn VP Regulatory & VP R&D Venture Capital, and Health-Tech MD, Ph.D. MD, Ph.D. Clinical Affairs • Formerly with MD with Bay City Venture Fund Lyon, France Madrid, Spain Capital • Formerly with Evonik Industries, Pfizer, Alcon, JNJ Ethicon, Ipsen Alcon Ciba Vision David Guyer, MD Bram Vanparys Antonio Fea, Norbert Pfeiffer, • Co-Founder & • Partner, Gimv Dan Scherrer Nadia Verwilghen Chairman of MD, Ph.D. MD, Ph.D. VP Operations VP Finance Ophthotech Corp. Torino, Italy Mainz, Germany • Formerly with • Formerly Auditor DePuy Spine at PWC and CFO at (JNJ), Synthes, MCI WorldCom, Biwi ABB, ASL Airlines Marty Wax, MD Marc Nolet de Brian Flowers, MD Steven Vold, MD • CMO and Brauwere Fayetteville, USA Executive VP of Dallas, USA • CEO of PhysIOL (cutting-edge IOLs) R&D at PanOptica, Inc.

Anne Portwich • Partner, LSP

Progressive, sight- Associated with elevated Intraocular Pressure threatening disease, (IOP) in most cases largely asymptomatic Blocked drainage canal builds up Second cause of blindness fluid after macular degeneration worldwide22

Excess fluid increases pressure which damages optic nerve

>80 >100 million million Proven therapeutic options aim at lowering IOP people people1

Sources: 1. Market Scope estimates for Glaucoma prevalence (August 2020) 2. WHO/NMH/PBD/12.01 – Global data on visual impairments 2010 & Glaucoma Devices: Progress On 2016 2021 Multiple Fronts, Elsevier Business Intelligence, April 2013

Disease progression

Mild Moderate Severe Refractory

Eye drops Traditional Surgery MIGS Safe and fast procedure Fastest growing market segment… • Largely dependent upon • Invasive and associated with Patient Compliance complications • Significant side-effect from ▪ Fibrotic reactions eye drops (ocular surface ▪ Patient maintenance disease) (bleb)

STAR® MINIjectTM

Medical grade silicone with precision-pore geometry A supraciliary MIGS implant made of STAR® anti-fibrotic Soft, flexible, tissue-friendly material Developed at the University of Washington, Seattle, USA

iSTAR has exclusive rights in Ophthalmology MINIject Patents Granted to iSTAR to the STAR® anti-fibrotic material

Cornea Iris

Exceptional No Encapsulation STAR implant Biointegration

observed as shown by the Choroid of the device with surrounding tissue colonizing absence of a continuous the porous structure while surrounding fibrous capsule, Retina preserving in vivo drainage nor continuous macrophage, Sclera efficacy nor a continuous fibroblast layer

Source: Prof. Nathalie Collignon (CHU of Liège, Liège, © iSTAR Medical. Confidential. Belgium); In-vivo: CER Groupe (Marloie, Belgium); Histology: GIGA-ULg Immunohistology Platform (University of Liège, Liège, Belgium). March 2013. 7 MIGS Clinical Performance Indicators

Meds (Eye-drops) Intra-ocular Pressure (IOP)

As low as possible Under control • Highest % of patients off eg. 10 to 20 mmHg meds depending on disease • Lowest use of meds to severity achieve target IOP

MIGS Performance Re-Intervention Safety (SAE, ECL,…)

As low as possible As low as possible • Lowest SAE rate • Secondary Incisional • No impact on endothelial Surgery corneal cells • Needling (sub-conj) • No impact on visual field and acuity

Meds (Eye-drops) Intraocular Pressure (IOP)

48% Meds-free Mean 13.8 mmHg

1.1 mean active 41% reduction ingredients

MINIject Best in Class Performance Re-Intervention Safety (SAE, ECL,…) (for Glaucoma)

No Ocular SAE None Mean ECL < 5%

The next generation MIGS • Micro-invasive technology which is safe and intuitive made of anti-fibrotic to implant in the supraciliary space medial grade silicone • Strong IP around anti-fibrotic STAR® material, device STAR® material design and implantation method

• Designed for powerful and enduring IOP reduction

• STAR-I trial highly positive efficacy and safety data supports use and excellent patient acceptance for vast majority of mild-moderate glaucoma patients

• Extensive clinical program evaluating the efficiency and safety with market access to CE countries and MINIject USA